Torno Capital’s Cytokinetics CYTK Stock Holding History

Torno Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$77.3K	–	303
2023 Q4	$83.5K	Buy	+1,000	New	+$36.2K	0.02%	188

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Torno Capital's CYTK Position: Q1 2024 in Review

Torno Capital sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 1,000 shares — an estimated $77.3K sold.

Torno Capital first reported a position in CYTK in Q4 2023 and held it in 1 quarter. The position peaked at $83.5K in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

Torno Capital reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
Torno Capital sold 1,000 Cytokinetics shares in Q1 2024, an estimated $77.3K.
Torno Capital first reported a position in Cytokinetics in Q4 2023 and held it in 1 quarter.
Torno Capital's Cytokinetics position peaked at $83.5K in Q4 2023.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Torno Capital's 13F filing for Q1 2024, filed 15 May 2024.